مباشر
FierceBiotechNovartis narrows focus for anticoagulant after failure to best Eliquis in phase 3 trialAgilentAgilent Technologies, Inc. $A Shares Sold by OVERSEA CHINESE BANKING Corp Ltd - MarketBeatWatersWaters introduces biphenyl LC columns with low UV bleed and wide pH stability for improved aromatic separations - Chromatography TodayLonza NewsSimulations Plus partners with Lonza and FDA on drug formulation research - Investing.com IndiaLonza NewsAcetylacetone Market: Asia Dominates with Lonza, Daicel, Wacker Boosting Specialty Chemicals Demand - openPR.comIlluminaCSR News Feed | Explore the latest corporate social responsibility news from Illumina - IlluminaThermo FisherThermo Fisher (TMO) Reports Q1: Everything You Need To Know Ahead Of Earnings - StockStory10x Genomics Blog10x Genomics: Atera Platform Launch Advances Spatial Biology With Single-Cell Resolution At Scale - Pulse 2.0Lonza NewsSimulations Plus partners with Lonza and FDA on drug formulation research - Investing.com AustraliaIlluminaCSR News Feed | Explore the latest corporate social responsibility news from Illumina - IlluminaFierceBiotechAACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave risesFierceBiotechRacing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS dataset
BioWorld ٢٥ فبراير ٢٠٢٦

Blossomhill Therapeutics reports new EGFR inhibitors

Blossomhill Therapeutics reports new EGFR inhibitors

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.